BioCardia, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BioCardia, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $479.0K | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $576.0K | Mar 16, 2018 |
| FY2017 | Dec 31, 2015 | $904.0K | Mar 16, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $12.0K | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Mar 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $62.0K | Mar 22, 2013 |
| FY2011 | Dec 31, 2011 | $12.0K | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Mar 29, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.23M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($7.95M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($11.57M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($11.91M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($12.62M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($15.00M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($14.71M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($13.99M) | Apr 9, 2020 |
| FY2019 | Dec 31, 2017 | ($12.31M) | Apr 9, 2020 |
| FY2018 | Dec 31, 2016 | ($10.31M) | Apr 2, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.28M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($8.00M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($11.64M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($11.90M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($12.63M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($15.53M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($14.21M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($14.10M) | Apr 9, 2020 |
| FY2019 | Dec 31, 2017 | ($12.41M) | Apr 9, 2020 |
| FY2018 | Dec 31, 2016 | ($7.61M) | Apr 2, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.96M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.39M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $7.73M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $8.83M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $8.56M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $9.81M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $8.56M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $8.45M | Apr 9, 2020 |
| FY2019 | Dec 31, 2017 | $5.80M | Apr 9, 2020 |
| FY2018 | Dec 31, 2016 | $3.33M | Apr 2, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.32M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.67M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $4.40M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $4.42M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.09M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $5.86M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $6.00M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.76M | Apr 9, 2020 |
| FY2019 | Dec 31, 2017 | $6.40M | Apr 9, 2020 |
| FY2018 | Dec 31, 2016 | $4.11M | Apr 2, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.44M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($7.89M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($9.97M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($10.56M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($10.37M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($12.36M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($9.45M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($11.07M) | Apr 9, 2020 |
| FY2019 | Dec 31, 2017 | ($8.67M) | Apr 9, 2020 |
| FY2018 | Dec 31, 2016 | ($5.52M) | Apr 2, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.0K | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.0K | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $12.0K | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $70.0K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $116.0K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $32.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $146.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $66.0K | Apr 9, 2020 |
| FY2019 | Dec 31, 2017 | $136.0K | Apr 9, 2020 |
| FY2017 | Dec 31, 2015 | $125.0K | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.41M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.72M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $2.99M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $9.79M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $15.72M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $23.42M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $7.68M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $6.42M | Apr 9, 2020 |
| FY2018 | Dec 31, 2017 | $13.54M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $22.08M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.52M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.89M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $4.59M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $4.90M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.34M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $4.25M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.31M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.63M | Apr 9, 2020 |
| FY2018 | Dec 31, 2017 | $2.41M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | $1.50M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $895.0K | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $837.0K | Mar 24, 2026 |
| FY2025 | Dec 31, 2023 | ($1.60M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2022 | $4.89M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $10.38M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $19.18M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $2.37M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $3.79M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $11.13M | Apr 9, 2020 |
| FY2019 | Dec 31, 2016 | $20.58M | Apr 9, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($168.35M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($160.12M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($152.18M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($140.60M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($128.70M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($116.07M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($101.07M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($86.36M) | Apr 9, 2020 |
| FY2018 | Dec 31, 2017 | ($72.45M) | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | ($60.14M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.50M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.37M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.10M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $7.36M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $12.87M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $21.41M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.59M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.36M | Apr 9, 2020 |
| FY2019 | Dec 31, 2017 | $12.69M | Apr 9, 2020 |
| FY2019 | Dec 31, 2016 | $21.35M | Apr 9, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.76M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 4.60M | Mar 24, 2026 |
| FY2023 | Dec 31, 2023 | 23.67M | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | 20.08M | Mar 29, 2023 |
| FY2021 | Dec 31, 2021 | 16.87M | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | 16.30M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 6.83M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 4.85M | Apr 9, 2020 |
| FY2018 | Dec 31, 2017 | 38.22M | Apr 2, 2019 |
| FY2017 | Dec 31, 2016 | 38.13M | Mar 16, 2018 |